Editors: Atta-ur-Rahman , M. Iqbal Choudhary

Frontiers in Cardiovascular Drug Discovery

Volume 2

eBook: US $59 Special Offer (PDF + Printed Copy): US $148
Printed Copy: US $119
Library License: US $236
ISSN: 2452-3267 (Print)
ISSN: 1879-6648 (Online)
ISBN: 978-1-60805-969-0 (Print)
ISBN: 978-1-60805-968-3 (Online)
Year of Publication: 2015
DOI: 10.2174/97816080596831150201

Introduction

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Indexed in: Book Citation Index, EMBASE, Chemical Abstracts, EBSCO.

Foreword

Cardiovascular disease (CVD) remains the major threat to health throughout the Westernized World. Although tremendous advances have been made during recent decades in the prevention and treatment of CVD, still CVD, including heart disease (coronary heart disease/CHD, hypertension/HTN, heart failure, and atrial fibrillation/AF) and stroke combine to cause more morbidity and mortality than cancer and any other diseases. Therefore, the prevention and treatment of CVD remains a major emphasis to clinicians, scientists, and the lay public.

Professor Dr. ATTA-UR-RAHMAN and Prof. Dr. IQBAL CHOUDHARY have contributed substantially during recent decades on many important topics related with health and CVD, particularly in the fields of natural products and bio-organic chemistry. In this new book, Volume 2 Frontiers in Cardiovascular Drug Discovery, they, along with the authors and co-authors of the chapters, provide substantial new and innovative information for the potential of natural substances (Traditional Chinese medicine, herbs, dietary nutitional substances, vitamins, tea, omega-3 fatty acids or fish oils, garlic, coenzyme Q 10, etc.) to protect against and to treat CVD, including the potential to prevent and treat atherosclerosis and CHD, the true # 1 killer in the Westernized World. There are also very detailed and comprehensive discussions of the vitamin K antagonists and the new alternatives to this therapy to prevent thromboembolic events, especially stroke, in non-valvular AF, which has been increasing in epidemic proportions in much of modern society. There is also a very interesting discussion of sympathetic nerve modulation as a potential alternative to pharmacological treatment that could become applicable to the treatment of millions of patients with HTN.

This book adds admirably to the large collection of work that these authors have provided, and this book should be of substantial interest to the clinical and scientific readership, particularly those interested in natural and innovative efforts for the prevention and treatment of CVD. I highly recommend reading this very interesting piece of work!

Carl J. Lavie
John Ochsner Heart and Vascular Institute
Professor of Medicine
Ochsner Clinical School-UQ School of Medicine
USA